Status:
COMPLETED
Almitrine in COVID-19 Patients With ARDS Treated by HFNO
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
ARDS
Hypoxemia
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to determine the effects of Almitrine administration on oxygenation in COVID-19 patients with acute respiratory distress syndrome treated by high-flow nasal canula oxygen ...
Detailed Description
From December 2019, the emergent coronavirus SARSCoV-2 is responsible for the worldwide pandemic of coronavirus disease (COVID-19). Although SARSCoV-2 infection is mainly responsible for mild respirat...
Eligibility Criteria
Inclusion
- Patients treated by high-flow nasal canula oxygen
- Positive COVID-19 real-time reverse transcriptase-polymerase chain reaction assay in nasal swabs
- Persistent severe hypoxemia after awake prone positioning defined by one or more of the following criteria:
- SpO2 \< 96% with FiO2 \> 80%
- PaO2/FiO2 ratio \< 100 with FiO2 \> 80%
- Patients treated by Almitrine
Exclusion
- Age \<18 years old and pregnant women
- Patients under legal protection
- Patients with a do not intubate or do not resuscitate decision
- Patients requiring immediate invasive mechanical ventilation
- Contraindication to Almitrine
- Poor echogenicity
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2022
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT05216575
Start Date
January 1 2021
End Date
January 31 2022
Last Update
April 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de NICE
Nice, France, 06200